VRTX (Vertex Pharmaceuticals) Days Payable : 84.10 (As of Sep. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Vertex Pharmaceuticals Days Payable?

Vertex Pharmaceuticals's average Accounts Payable for the three months ended in Sep. 2024 was $362 Mil. Vertex Pharmaceuticals's Cost of Goods Sold for the three months ended in Sep. 2024 was $393 Mil. Hence, Vertex Pharmaceuticals's Days Payable for the three months ended in Sep. 2024 was 84.10.

The historical rank and industry rank for Vertex Pharmaceuticals's Days Payable or its related term are showing as below:

VRTX' s Days Payable Range Over the Past 10 Years
Min: 60.16 Med: 87.07 Max: 360.65
Current: 89.87

During the past 13 years, Vertex Pharmaceuticals's highest Days Payable was 360.65. The lowest was 60.16. And the median was 87.07.

VRTX's Days Payable is ranked worse than
59.1% of 714 companies
in the Biotechnology industry
Industry Median: 127.14 vs VRTX: 89.87

Vertex Pharmaceuticals's Days Payable declined from Sep. 2023 (105.78) to Sep. 2024 (84.10). It may suggest that Vertex Pharmaceuticals accelerated paying its suppliers.

Vertex Pharmaceuticals Days Payable Historical Data

The historical data trend for Vertex Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Days Payable Chart

Vertex Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

66.16

60.16

70.66

84.28

96.70

Vertex Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Payable	Get a 7-Day Free Trial															105.78	91.85	95.39	83.34	84.10

Competitive Comparison of Vertex Pharmaceuticals's Days Payable

For the Biotechnology subindustry, Vertex Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vertex Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Days Payable falls into.

Vertex Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Vertex Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (303.9	+	364.9)	/	2 )	/	1262.2	*	365
=	334.4					/	1262.2	*	365
=	96.70

Vertex Pharmaceuticals's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

	Days Payable (Q: Sep. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (327.9	+	395.8)	/	2 )	/	392.6	*	365 / 4
=	361.85					/	392.6	*	365 / 4
=	84.10

Vertex Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Vertex Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (NAS:VRTX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

VRTX:Mexico 1VRTX:Italy 0QZU:UK VX1:Germany VX1:Germany VX1:Germany VRTX34:Brazil VRTX:Austria

Address

50 Northern Avenue, Boston, MA, USA, 02210

Website

https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Executives

David Altshuler	officer: EVP, Global Research and CSO	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Wagner Charles F Jr	officer: EVP & Chief Financial Officer	C/O MILLIPORE CORP, BILLERICA MA 01820
Reshma Kewalramani	director, officer: CEO & President	C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Jonathan Biller	officer: EVP and Chief Legal Officer	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jeffrey M Leiden	director	15 N BEACH ROAD, HOBE SOUND FL 33455
Sangeeta N. Bhatia	director	C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Carmen Bozic	officer: EVP and CMO	C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Bruce I Sachs	director	C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Atkinson Edward Morrow Iii	officer: EVP, Chief Technical Ops. Off.	C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104
Ourania Tatsis	officer: EVP, Chief Reg. & Quality Off.	C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Kristen Ambrose	officer: SVP & Chief Accounting Officer	C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON MA 02210
Stuart A Arbuckle	officer: EVP, COO	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139
Amit Sachdev	officer: SVP, Public Policy,Gov Affairs	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Michel Lagarde	director	450 LEXINGTON AVE., 31ST FLOOR, NEW YORK NY 10017
Terrence C Kearney	director	IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045